Companies › Scancell
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SCIB1 DNA vaccine encoding modified gp100 and TRP-2 to stimulate anti-tumor immunity | – | Phase 2 | Malignant Melanoma | Jan 2027 |
| Modi-1 Moditope Personalized neoantigen vaccine | – | Phase 1 | Triple Negative Breast Cancer | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04079166 | SCIB1 | Phase 2 | Malignant Melanoma | Oncology | Jan 2027 |
| NCT04079166 | SCIB1 | Phase 2 | Malignant Melanoma | Oncology | Jan 2027 |
| NCT05329532 | Modi-1 Moditope | Phase 1 | Triple Negative Breast Cancer | Oncology | Jul 2027 |
No annotated target.
–
Allotera Therapeutics Diakonos Oncology Beijing Yongtai Ruike Biotechnology Company Imbioray (Hangzhou) Biomedicine ImmVira Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.